Publications
Updating Systematic Reviews - their importance and techniques for updating, A Tsertsvadze, S Stoddart, M Plested, 2009 Read more >>
Reporting quality of double-blind randomized controlled trials and its association with the funding agency, Agrawal R, Dimri S, Ubhadiya BS, Narvilkar P, Bhanderi M, 2009 Read more >>
Type 2 diabetes - influence of lifestyle change?, Arora A, Aneja G, Shukla H, Alnwick K, 2009 Read more >>
Diagnosis and treatment of overactive bladder in Evidence-based urology,, Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun C, Weinstein D, Kopp Z, 2009 Read more >>
An exploratory analysis of reasons behind premature termination of randomized controlled trials, Dimri S, Ubhadiya BS, Singh N, Narvilkar P, Bhanderi M, 2009 Read more >>
Review and chronology of smoking cessation models, Fisher M, Muston D, Knight C, 2009 Read more >>
Use of indirect comparison in HTA submissions, Glassup F, Modha R, Muston D, Kerrigan J, Misra A, Williams R., 2009 Read more >>
Pharmacogenomics: Applicability in Antiretro Viral Therapy (ART) in HIV Patients, Goyal R, Rai MK, Chawla A, Siddiqui MK, Srivastava K, 2009 Read more >>
The impact of the submission sequence – which appraising body to submit to first?, Karia R, Plested M., 2009 Read more >>
Relevance of conference abstracts and hand-searching in systematic reviews, Karia R, Zwaferink H, Malik M, 2009 Read more >>
An economic evaluation of topical treatments for actinic keratosis, Muston D, Downs T, Rives V, 2009 Read more >>
A comparison of policies on paediatric dosing guidelines and indications between the United States and Europe, Nixon F, Chan M, 2009 Read more >>
Systematic review reliability: efficacy of two independent reviewers and two step reviews, Pietri G and Muston D, 2009 Read more >>
A comparison of reasons for recommendation and rejection across four health technology appraisal systems categorised by disease., Plested M, Karia R, Samuels E., 2009 Read more >>
Pharmacoeconomic Relevance of Antiretro Viral Therapy (ART) in Low and Middle Income Countries, Rai MK, Goyal R, Srivastava K, Siddiqui MK, Chawla A, Joshi B, Sehgal M., 2009 Read more >>
Where is the current focus of health economics? An investigation into the published literature within three key health economics journals, Samuels E, Phiri D, 2009 Read more >>
Rehabilitation of older patients: day hospital compared to rehabilitation at home. A randomised controlled trial, SG Parker, P Oliver, M Pennington, J Bond, C Jagger, PM Enderby, R Curless, T Chater, A Vanoli, K Fryer, C Cooper, S Julious, C Donaldson, C Dyer, T Wynn, A John, D Ross, 2009 Read more >>
Incidence rate and burden of illness of cervical cancer in United States of America., Srivastava K, Rai MK, Siddiqui MK, Goyal R, Chawla A, Takyar S, Sharma S., 2009 Read more >>
Socio-economic impact of avian influenza in South-East Asia and neighbouring high risk countries., Arora M, Srivastava K, Siddiqui MK, Verma J, Ahuja M, Sharma S, 2008 Read more >>
Quality of life measurement in current clinical trials: focus on chronic diseases, Bhanderi M, Singh N, Kumar R, Chawla A, Sehgal M, 2008 Read more >>
A comparison of reasons for recommendation and rejection in four health technology appraisal systems: NICE, SMC, CADTH and PBAC, Cann K, Karia R, Plested M, Samuels E., 2008 Read more >>
The safety and tolerability of antimuscarinic treatments in overactive bladder: results from an update of a systematic review and meta-analysis, Chapple C, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D, 2008 Read more >>
The Effects of Antimuscarinic Treatments in Overactive Bladder:An Update of a Systematic Review and Meta-Analysis, Chapple C, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D, Kopp Z., 2008 Read more >>
Pharmacogenomics: relevance and applicability in post-genomic era (HIV-therapy)., Chawla A, Kumar R, Aneja G, Bhanderi M, Seghal M, 2008 Read more >>
Economic implications of severe digital ulcer disease - a cost of illness analysis of patients receiving specialized care in the UK, Denton CP, Nihtyanova S, Hunsche E, Gani R., 2008 Read more >>
Cost-effectiveness analysis of natalizumab compared with other disease modifying treatments for people with highly active relapsing-remitting multiple sclerosis in the UK, Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, et al, 2008 Read more >>
A cost effectiveness analysis of natalizumab vs. interferon-beta and glatiramer acetate in patients with active relapsing-remitting multiple sclerosis currently failing on existing therapy., Gani R, Samuels ER, Hughes S, Giovanonni G., 2008 Read more >>
Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model - application to a population of US adult smokers, Howard P, Knight C, Boler A, Baker C., 2008 Read more >>
Inappropriate sedation in ICUs: evidence from the literature, Jackson D, Proudfoot CW, Knight CJ, Cann K, Lock K, 2008 Read more >>
A comparison of three technology appraisal systems: NICE, SMC and CADTH., Karia R, Gani R, Perard R and Cann K., 2008 Read more >>
Update of results and outcomes of NICE single technology appraisals & economic criticisms, Karia R, Plested M, Cann K, Zwaferink H., 2008 Read more >>
The patient perceived effects of antimuscarinic treatment: results from an update of a systematic review and meta-analysis, Khullar V, Chapple C, Gabriel Z, Muston D, Bitoun CE, Weinstein D., 2008 Read more >>
A systematic review of the characteristics of randomised control trials featuring prostaglandins for the treatment of glaucoma, Lee CW, Buckley F, Costello S, Kelly S., 2008 Read more >>
The RCT evidence of comparative effectiveness and safety of topical glaucoma medication, Lee CW, Buckley F, Costello S, Stoddart SD, Kelly S., 2008 Read more >>
Systematic review and meta-analysis of RCTs regarding the comparative incidence of hyperaemia of prostaglandin topical glaucoma medications, Lee CW, Stoddart SD, Muston D, Buckley F, Costello S, Kelly S, 2008 Read more >>
Trends in research into central nervous system disorders: the influence of an aging population., Lock K, Samuels E, 2008 Read more >>
Cost-effectiveness sensitivity to cost-effectiveness correlation: a simulation study, Muston D, 2008 Read more >>
Systematic review reliability: sensitivity and specificity of one vs. two reviews, Muston D, Alnwick K, 2008 Read more >>
Characteristics of risk-sharing schemes in Europe., Muston D, Perard R, Nixon F, 2008 Read more >>
Role of disease specific instruments in the measurement of Health-Related Quality of Life in cancer clinical trials, Narvilkar P, Mahajan A, Dimri S, Kumar R, Seghal M., 2008 Read more >>
The reimbursement of orphan drugs across Europe, Nixon F., 2008 Read more >>
Search strategies and results of systematic reviews, Proudfoot C, Plested M, Buckley F., 2008 Read more >>
What proportion of diseases are QALYS an irrelevant measure for?, Proudfoot CW, Alnwick K., 2008 Read more >>
Has the quality of randomized controlled trials increased with time: an analysis of data from 5 systematic reviews, Proudfoot CW, Stoddart SD, Muston D, 2008 Read more >>
Prevalence of research focuses on genetically-linked disorders: where have we been and where are we going?, Samuels E, Lock K, Karia R, Stoddart SD., 2008 Read more >>
Categorising research: where is the focus?, Samuels E, Plested M, 2008 Read more >>
Huntington’s disease: where have we been?, Samuels E, Stoddart SD, Lock K, Karia R., 2008 Read more >>
Design and reporting trends in piggy-back economic trials., Ubhadiya BS, Gautum C, Narvilkar P, Singh N, Bhanderi M, Dimri S, 2008 Read more >>
Evaluating the effectiveness of search strategies for systematic review, Buckley F, Proudfoot C, Boler A., 2007 Read more >>
Estimating the rates of disability progression in people with relapsing-remitting multiple sclerosis., Gani R, Nixon R, Hughes S, Jackson C., 2007 Read more >>
Assessing levels of association between health-care expenditure and health-care indicators in economically developed countries, Gani R, Ravndal F., 2007 Read more >>
Interventions that enhance medication compliance and persistence: theoretical grounding, and economic assessment, Hughes D, Sridhar F, Elliot R, Cowell W, Budhia S., 2007 Read more >>
Results and outcomes of NICE single technology appraisal process, Karia R, Gani R, Boler A, 2007 Read more >>
An evaluation of the cost-effectiveness of an extended course of varenicline in preventing smokers who have quit from relapsing, Knight C, Howard P, Baker C, 2007 Read more >>
Price vs. access: a probabilistic model for guiding pricing decisions, Muston D, Howard P., 2007 Read more >>
A practical guide to indirect/mixed treatment comparisons, Muston D,Boler A, 2007 Read more >>
Examining incentives for subgrouping in NICE submissions, Muston D., 2007 Read more >>
The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK, Orme M, Kerrigan J, Tyas D, Russel N, Nixon R, 2007 Read more >>
European pricing and reimbursement update: optimal monetary benefits can depend on which country the process is initiated, Perard R, Gani R, 2007 Read more >>
The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity?, Tyas N, Kerrigan J, Russel N, Nixon R, 2007 Read more >>
Disability progression rates in people with active relapsing-remitting multiple sclerosis, Gani R, Hughes S, Jackson C, Nixon R., 2006 Read more >>
Bowel cancer screening. Balancing cost-effectiveness and affordability, Howard P, Muston D., 2006 Read more >>
The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis, Khullar V, Chapple C, Gabriel Z, Dooley JA, 2006 Read more >>
A care map for CHF in the UK, Knight C., 2006 Read more >>
A model for projecting bowel cancer incidence and mortality: application to the UK bowel cancer screening program, Muston D, Howard P, Lee D. , 2006 Read more >>
Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: a systematic review of economic evidence, Orme M, Boler A, 2006 Read more >>
Body mass index (BMI) and trends in GP consultations and prescribing: A UK NHS perspective, Boler A, Lister S., 2005 Read more >>
Comparative safety and tolerability of antimuscarinic treatments for overactive bladder, Chapple C, Khullar V, Gabriel Z, Dooley J, 2005 Read more >>
Lumping versus Splitting: a comparison of two systematic reviews of antimuscarinic treatment for overactive bladder, Gabriel Z, Khullar V, Chapple C, Dooley J, 2005 Read more >>
Duloxetine compared with antimuscarinics for the treatment of mixed urinary incontinence: an assessment of adverse events and withdrawals., Khullar V, Chapple C, Gabriel Z, Dooley J., 2005 Read more >>
An exploration of patient factors in influencing prescriber activity in UK general practice., Richard L, Lister S, 2005 Read more >>
A preliminary analysis of the relationship between consultation length and prescriber activity in UK general practice, Richard L, Lister S., 2005 Read more >>
A review of the economic evidence for botulinum toxins in spasticity associated with stroke and cerebal palsy, Richard L, Odeyemi I, Ward A, 2005 Read more >>
The need for consensus in outcome measures for assessment of interventions for spasticity., Richard L, Odeyemi I, Ward A., 2005 Read more >>
A systematic review of the effectiveness of total and partial laparoscopic fundoplication for the treatment of GORD, Boler A,Howard P, 2004 Read more >>
Blood donation in the 21st century: motivation amidst crisis, Gabriel Z,Richard L, 2004 Read more >>
Cost effectiveness of latanoprost in first line treatment of primary open angle glaucoma in the UK, Gosden T, Costello S, Orme M, Howard P, Dooley J., 2004 Read more >>
A clinical and cost effectiveness comparison of venlafaxine and selective serotonin reuptake inhibitors (SSRIS) in the management of patients with major depressive disorder from the perspective of an Austrian sickness fund, Howard P, Knight C., 2004 Read more >>
Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK., Lenox-Smith A, Conway P, Knight C., 2004 Read more >>
The cost-effectiveness of methyl aminolevulinate photodynamic therapy (MAL-PDT) for basal cell carcinoma, Orme M, Howard P., 2004 Read more >>
The cost-effectivesness of methyl aminolevulinate photodynamic therapy (MAL-PDT) for difficult to treat actinic keratoses, Orme M, Howard P., 2004 Read more >>
Calculating the cost of wound care in a community setting in the UK: an example using modern wound management dressings, Orme M,Daniels S., 2004 Read more >>
A cost consequence analysis of new endoscopic, injectable treatment and existing interventions in gastro-oesophageal reflux disease., Boler A, Wenk-Lang A, Howard P., 2003 Read more >>
The implications of combining heterogeneous patient populations in meta-analyses., Boler A,Howard P, 2003 Read more >>
Equity, access and economic evaluation in rare diseases., Bosanquet N, Domeninghetti G, Beresniak A, Auray J, Crivelli L, et al, 2003 Read more >>
First and second year UK treatment costs associated with the use of anti-TNF drugs in patients with rheumatoid arthritis, Conway P,Knight C, 2003 Read more >>
The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes, Orme ME, Jurewicz WA, Kumar N, McKechnie TL, 2003 Read more >>
Pharmacoepidemiology: a review of its emerging role in outcomes research, Richard L., 2003 Read more >>
A review of the pharmacotherapeutic management of pulmonary arterial hypertension, Richard L., 2003 Read more >>
Cost-effectiveness analyses of TAXUS(TM) drug-eluting stent in the UK, Wenk-Lang A, Knight C., 2003 Read more >>
Trends in data sources used for economic evaluation, Boler A., 2002 Read more >>
Limitations of the methods used for calculating quality-adjusted life-year values, Duru G, Auray JP, Beresniak A, Lamure M, Paine A, et al, 2002 Read more >>
Funding decisions for anti-rejection therapies; the use of real costs and economic models to predict cost-effectiveness., Ready A, Yi-Hua C, Barratt R, Sen S, Knight C, et al, 2002 Read more >>
A review of the pharmacotherapeutic management of pulmonary arterial hypertension, Richard L, Howard P, Thorpe T., 2002 Read more >>
The relationship between disease area and type of economic study - does it exist, Richard L., 2002 Read more >>
Modern wound dressings are more cost-effective than traditional gauze dressings in managing difficult to heal surgical wounds, Daniels S, Kerrigan J., 2001 Read more >>
Funding restrictions for new anti-rejection therapies in the UK. Modelling for cost-effectiveness may provide a means of challenge, Ready A, Yi-Hua C, Barratt R, Sen S, Knight C, 2001 Read more >>
Estimating health state preferences in obesity, Hakim Z, Howard P, Farina C., 2000 Read more >>
Modelling of anti-obesity treatment: cost-effectiveness model in the UK, Knight C, Ratcliffe A, Howard P, Farina C, 2000 Read more >>
Pharmacoeconomic analysis of clodronate and pamidronate in osteolytic bone disease in Canada and the UK, Ilersich L, Howard P, 1999 Read more >>
A novel approach to markov modelling: a computer forecasting tool to model the costs and consequences of the management of the hepatitis C virus (HCV), Kerrigan J, Humphrey K, Duscheiko G, Foster G, Rosenberg W, 1999 Read more >>
Cost minimisation analysis of CHOP, fludarabine and rituximab for the treatment of relapsed, indolent B-cell non-hodgkins lymphoma in the UK., Sweetenham J, Hieke K, Kerrigan M, Howard P, Smarrt P, 1999 Read more >>
Cost minimisation analysis of CHOP, fludarabine and rituximab for the treatment of relapsed, indolent B-cell non hodgkins lymphoma in the UK, Sweetenham J, Hieke K, Kerrigan M, Howard P, Smarrt P, 1999 Read more >>
Cost minimisation analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-hodgkins lymphoma in the UK, Howard P, Hieke K, Kerrigan M, Smarrt P, McIntyre A, et al, 1998 Read more >>
Comparative economic analysis of the treatment of relapsed low-grade B-cell non-hodgkins lymphoma (NHL) using CHOP, fludarabine or rituximab, Sweetenham J, McIntyre A, Howard P, Smarrt P, Kerrigan M, et al., 1998 Read more >>
A COST-EFFECTIVENESS ANALYSIS OF A DRUG ELUTING STENT IN THE UK.,
LIFETIME UTILITY GAIN (LUG) AND THE LIFE YEARS GAINED (LYG) CONSIDERED AS AN AID TO FUNDING DECISIONS FOR HEALTH CARE PROFESSIONALS.,